Clinical Trial Update: Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating Lu-PSMA-617 for oligometastatic prostate cancer treated with stereotactic ablative radiotherapy; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• Pluvicto (lutetium-177 PSMA-617)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Oligometastatic Prostate Cancer | Phase 2 | Status: RECRUITING